Australia Nutraceuticals Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia nutraceuticals market is maturing into a premium, evidence-led category. Supplement use is already mainstream, so growth now depends on better formulations, new delivery formats such as gummies and powders, and credible health claims rather than on new users alone.

Three forces are shaping the market: broad adoption, with 74% of Australians using supplements in the past year according to Complementary Medicines Australia; tighter oversight, as the Therapeutic Goods Administration places listed medicine advertising among its priority areas; and export pull, with shipments above AUD 1 billion and China taking 68%.

In August 2025 Swisse reported steady growth in Australia and New Zealand, in March 2026 Clover reported higher half-year profit on omega-3 DHA powders, and in July 2026 Blackmores launched its first cognition tablet in Australian pharmacies from September.

Key Market Trends and Insights

• Mainstream consumer base: Complementary Medicines Australia reports that 74% of Australians used supplements in the past year, and 41% take them daily, which keeps replenishment demand steady.
• Retail scale: The industry body puts retail sales of complementary medicines at about AUD 6.3 billion in 2025, with pharmacies holding roughly 61% of vitamin and dietary supplement sales.
• Export pull: NutraIngredients reported in December 2025 that Australian supplement exports exceed AUD 1 billion, with China at 68% and Vietnam second at 8%.
• Regulatory scrutiny: The Royal Australasian College of Physicians said in July 2026 that only about 2% of newly listed medicines had published efficacy assessments, which raises pressure for evidence-backed claims.

Australia Nutraceuticals Market Size and Forecast

The market is moving from basic multivitamins towards targeted products for sleep, cognition, gut health, beauty and healthy ageing, delivered as gummies, powders and ready-to-drink formats. Vitamins and minerals lead in value because they anchor pharmacy ranges, while probiotics and prebiotics advance fastest as digestive and immune positioning broadens. Pharmacies remain the main channel, and online and direct-to-consumer sales gain share through marketplaces and subscription models. New South Wales remains the largest region, and Queensland grows quickest on population inflows and an active outdoor lifestyle. Stronger evidence requirements, new ingredient pathways and export demand from Asia point to a durable shift towards premium, claim-backed products rather than a short cycle of growth.

Key Takeaways: Australia Nutraceuticals Market

Mainstream Use Anchors Long-Term Demand

Revenue is on course to expand by about 57% across the decade, from AUD 8.50 billion in 2025 to AUD 13.33 billion in 2035 at a 4.6% CAGR. With 74% of Australians using supplements and 84% confident in their safety and quality, repeat purchasing underpins steady volume.

Targeted Formats and Digital Channels Lead Growth

Vitamins and Minerals hold the largest share, but Probiotics and Prebiotics grow at an estimated 6.2% CAGR and Online and Direct-to-Consumer sales at an estimated 6.8% through 2035. Swisse launched a magnesium glycinate tablet and a children's gummy range in 2025, showing how brands target specific needs.

Evidence Rules Reshape Claims and Exports

Regulators are tightening scrutiny of listed medicines at the same time as exports exceed AUD 1 billion, so brands that can prove efficacy and quality gain an advantage at home and in Asia.

• TGA names listed medicine advertising a priority in its 2026 and 2027 principles
• Royal Australasian College of Physicians study of July 2026 questions efficacy evidence
• China takes 68% of exports and Vietnam 8%, led by online channels

Australia Nutraceuticals Market Report Summary

Key Insight

Supplement use is mainstream, so growth now comes from targeted formulations, new formats and claims backed by evidence. New South Wales leads, while Queensland grows fastest.

Key Trends in the Australia Nutraceuticals Market

The Australia nutraceuticals market is being shaped by tighter regulatory scrutiny, export diversification, evidence-based claims and the rise of online buying.

July 2026 - Physicians' College Study Questions Efficacy Evidence for Listed Medicines

• The Royal Australasian College of Physicians said on 17 July 2026 that only about 2% of newly listed medicines had published efficacy assessments.
• Of 62 efficacy reviews, 33 found the sponsor lacked substantial evidence or that some claims were not permitted.
• Brands with clinical data and compliant wording may gain share as scrutiny rises.

March 2026 - TGA Publishes Compliance Principles for 2026 and 2027

• Stephens Lawyers reported in March 2026 that listed medicine advertising is priority area four of twelve.
• The principles target non-compliance on digital channels, including influencers and online marketplaces.
• Brands relying on social media promotion therefore need tighter claim checks before each campaign.

December 2025 - TGA Reviews Listed Medicines Containing Valerian, Glutathione and Resveratrol

• The December 2025 update to the Therapeutic Goods Administration compliance reports covered 19 listed medicines.
• Reviews examined named ingredients and claims such as anxiety, liver regeneration, oestrogen and weight loss.
• Non-compliant products face risk-based regulatory action, which favours sponsors with documented evidence.

December 2025 - Exports Diversify Beyond China as Online Sales Grow in Asia

• NutraIngredients reported on 8 December 2025 that Australian supplement exports exceed AUD 1 billion.
• China including Hong Kong takes 68%, Vietnam 8%, New Zealand 3%, South Korea 3% and Thailand 3%.
• Online channels pass 60% of China supplement sales, which rewards brands with strong digital operations.

Key Insight

Regulators are scrutinising efficacy claims and online advertising, while export markets widen beyond China, so evidence, compliance and digital capability decide which brands gain share.

Recent Market Developments in the Australia Nutraceuticals Market

Recent developments, presented from the most recent, show retail scale at Chemist Warehouse, a new Blackmores cognition launch, Swisse momentum in Australia and omega-3 demand at Clover.

August 2026 - Sigma Healthcare Reports Own-Label Sales Near AUD 1 Billion

• Sigma Healthcare reported on 27 August 2026 revenue of AUD 10.8 billion and 24 new Chemist Warehouse stores, taking the network to 561.
• Own and exclusive label products generate close to AUD 1 billion in annual sales, with more than 470 launched.
• Retail scale lets pharmacy chains push private-label vitamins and supplements.

July 2026 - Blackmores Launches Cognition Ultra with Cognizin Citicoline

• Kirin and Blackmores announced on 24 July 2026 Blackmores Cognition Ultra, its first product designed to enhance cognitive performance.
• Each tablet carries 250 mg of Cognizin Citicoline, and Australian pharmacies stock it from September 2026.
• It is made at Braeside and sells online for AUD 45.00 per 30-tablet pack.

July 2026 - H&H Group Reports Double-Digit Growth in Australia and New Zealand

• H&H Group announced on 5 July 2026 that adult nutrition revenue rose in the low to mid teens in its first-half update.
• Australia and New Zealand grew by double digits, and Swisse sales on Douyin rose by more than 50%.
• Domestic demand and cross-border channels now support Swisse together.

March 2026 - Clover Reports Higher Half-Year Profit on Omega-3 DHA Powders

• Clover announced on 24 March 2026 half-year revenue of AUD 44.1 million and net profit after tax of AUD 4.2 million.
• Growth was supported by non-allergenic, higher-fortification and plant-based DHA powders and wider distribution.
• Full-year revenue guidance of AUD 92 million to AUD 96 million signals continued ingredient demand.

Key Insight

Pharmacy private labels, a first cognition product from a leading brand, strong Swisse growth and marine oil ingredient demand show investment in premium, targeted nutraceutical ranges.

Australia Nutraceuticals Industry Segmentation

The Expert Market Research’s report on the Australia Nutraceuticals Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Vitamins and Minerals
• Herbal and Botanical Supplements
• Probiotics and Prebiotics
• Omega-3 and Collagen Supplements
• Functional Foods and Beverages
• Others

Vitamins and Minerals lead on value, in our estimate, because pharmacy ranges and daily-use habits are built on them, and Swisse launched a magnesium glycinate tablet in 2025. Probiotics and Prebiotics grow fastest at an estimated 6.2% CAGR through 2035 on gut and immune positioning. Herbal and Botanical Supplements grow steadily as the Therapeutic Goods Administration reviewed valerian-containing listed medicines in December 2025. Omega-3 and Collagen Supplements benefit from Clover's March 2026 DHA powder growth and beauty demand. Functional Foods and Beverages add convenient everyday formats, and Sigma Healthcare's close to AUD 1 billion of own and exclusive label sales in August 2026 shows retailers pushing wellness lines.

Market Breakup by Form

• Capsules and Tablets
• Powders
• Gummies and Chewables
• Liquids and Ready-to-Drink
• Others

Capsules and Tablets lead, in our estimate, because pharmacy shoppers favour them, as seen in Blackmores Cognition Ultra, a 30-tablet pack launched in July 2026 at AUD 45.00. Gummies and Chewables grow fastest at an estimated 5.7% CAGR through 2035, as Swisse added six Little Swisse Kids Gummies in 2025. Powders benefit from Clover's non-allergenic DHA powders reported in March 2026 and from collagen and protein blends. Liquids and Ready-to-Drink cover shots, tonics and functional drinks. Others include sprays, patches and topical formats.

Market Breakup by Distribution Channel

• Pharmacies
• Supermarkets and Grocery
• Online and Direct-to-Consumer
• Health Stores and Practitioners
• Others

Pharmacies lead, in our estimate, holding about 61% of vitamin and dietary supplement sales according to Complementary Medicines Australia, and Sigma Healthcare's 561 Chemist Warehouse stores in August 2026 reinforce that scale. Online and Direct-to-Consumer grows fastest at an estimated 6.8% CAGR through 2035, helped by marketplaces and by Swisse's Douyin growth of more than 50% reported in July 2026. Supermarkets and Grocery sell mainstream vitamins and functional foods. Health Stores and Practitioners serve practitioner-only ranges and naturopathic advice.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• Others

New South Wales dominates, in our estimate, as the most populous state with Sydney's retail, pharmacy and manufacturing base, growing at an estimated 4.2% CAGR through 2035 from a large, mature base. Victoria grows at 4.4%, supported by Melbourne, where Clover's refinery and Swisse operate. Queensland is the fastest-growing region at an estimated 5.2% on population inflows and wellness demand. Western Australia grows at 4.9%. Others, grouping South Australia, Tasmania, the Australian Capital Territory and the Northern Territory, whose individual shares are small, grow at 4.5%.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Nutraceuticals Market

Competition combines Australian heritage brands, Asian-owned groups, ingredient manufacturers and pharmacy chains with private labels. Entry barriers include Therapeutic Goods Administration compliance, good manufacturing practice licences, clinical evidence, pharmacy relationships and export channel knowledge.

Blackmores

Blackmores, headquartered in Warriewood, New South Wales, is a Kirin Group company selling vitamins, minerals and herbal supplements across Australia, New Zealand and Asia. In July 2026 it announced Blackmores Cognition Ultra, with 250 mg of Cognizin Citicoline per tablet, made at its Braeside site. Online sales started in late July, and Australian pharmacies follow from September 2026, which extends its range into cognitive health.

Swisse

Swisse, a Melbourne-based wellness brand owned by Guangzhou-based H&H Group, sells multivitamins, beauty-from-within and healthy ageing products. In August 2025 H&H reported that Swisse delivered steady growth in Australia and New Zealand and launched a magnesium glycinate tablet and Little Swisse Kids Gummies. In July 2026 the group said Australia and New Zealand again grew by double digits.

Clover Corporation

Clover Corporation, based in Altona North, Victoria, makes omega-3 DHA and ARA ingredient powders for supplements and infant formula from a Melbourne refinery. In March 2026 it reported half-year revenue of AUD 44.1 million and profit after tax of AUD 4.2 million, up from AUD 2.4 million. New non-allergenic and plant-based DHA powders supported the result, and full-year revenue guidance is AUD 92 million to AUD 96 million.

Sigma Healthcare

Sigma Healthcare, headquartered in Melbourne, runs Chemist Warehouse, Amcal and Discount Drug Stores, a major route to market for vitamins and supplements. In August 2026 it reported revenue of AUD 10.8 billion, 24 new Chemist Warehouse stores and close to AUD 1 billion in own and exclusive label sales. More than 470 such products launched, and a growing private-label range competes directly with established supplement brands.

Other players operating in the Australia nutraceuticals market include Vitaco Health Group, Cenovis, Ainsworth Pharmaceuticals, Nutrition Care Pharmaceuticals, and Pharmacare Laboratories, alongside contract manufacturers, practitioner brands, online-only labels and ingredient suppliers serving pharmacies, supermarkets, health stores and export customers across Australia.

Key Insight

Competition rests on brand trust, clinical evidence, regulatory compliance, pharmacy relationships and digital reach, while private labels and ingredient innovation keep pressing established supplement brands.